结核病内科治疗的现状与展望

被引：5

作者：

唐神结

肖和平

机构：

[1] 同济大学附属上海市肺科医院结核病诊疗中心

来源：

结核病与肺部健康杂志 | 2012年 / 1卷 / 01期

关键词：

结核/治疗; 药物疗法; 免疫疗法; 结核菌苗; 纳米技术;

D O I：

暂无

中图分类号：

R52 [结核病];

学科分类号：

1002 ; 100201 ;

摘要：

结核病的内科治疗从最初的静养疗法、萎陷疗法,到1944年链霉素的问世及化学治疗时代,再到1965年利福平的问世及短程化疗时代,以及今天的化疗、免疫、介入等多种治疗并举的时代。面对日益加剧的耐药结核病的流行趋势,结核病内科治疗的未来无疑应着眼于抗结核新药的研制与开发、结核病治疗性疫苗的研究,以及纳米技术在结核病中的应用等。

引用

页码：11 / 14

页数：4

共 29 条

[1]

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid); TMC207; PA-824; SQ109; and pyrazinamide..[J].Robert S Wallis;Wesley Jakubiec;Mark Mitton-Fry;Lynn Ladutko;Sheldon Campbell;Darcy Paige;Annette Silvia;Paul F Miller.PLoS ONE.2017, 1

[2] Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance [J].

Diacon, A. H. ;

Donald, P. R. ;

Pym, A. ;

Grobusch, M. ;

Patientia, R. F. ;

Mahanyele, R. ;

Bantubani, N. ;

Narasimooloo, R. ;

De Marez, T. ;

van Heeswijk, R. ;

Lounis, N. ;

Meyvisch, P. ;

Andries, K. ;

McNeeley, D. F. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) :3271-3276

[3] SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro [J].

Reddy, Venkata M. ;

Dubuisson, Tia ;

Einck, Leo ;

Wallis, Robert S. ;

Jakubiec, Wesley ;

Ladukto, Lynn ;

Campbell, Sheldon ;

Nacy, Carol A. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (05) :1163-1166

[4] In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis [J].

Kumar, Gaurav ;

Malhotra, Samir ;

Shafiq, Nusrat ;

Pandhi, Promila ;

Khuller, Gopal Krishan ;

Sharma, Sadhna .

JOURNAL OF MICROENCAPSULATION, 2011, 28 (08) :717-728

[5]

Nanomedicine as an emerging approach against intracellular pathogens.[J].Bingyun Li;Armstead.International Journal of Nanomedicine.2011, defa

[6]

Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis..[J].Smith Jonathan Paul.The Yale journal of biology and medicine.2011, 4

[7] Present Status of Nanoparticle Research for Treatment of Tuberculosis [J].